📊 This is a company profile preview from Tablestat.com Request a Free Trial Now

Company profile: Perspective Therapeutics

1.1 - Company Overview

Perspective Therapeutics Logo

Perspective Therapeutics

Headquarter: United States
Founded: 20XX🔒
Employees: 100-500🔒

Company description

  • Provider of radiopharmaceutical cancer theranostics and targeted alpha-particle radiotherapy, including Pb-203 diagnostics and Pb-212 treatment via targeting peptides. Offers clinical programs VMT-α-NET for neuroendocrine tumors and VMT01 for metastatic melanoma, and a proprietary Pb-212 isotope generator to secure key isotopes for clinical trials and commercial operations.

Products and services

  • Pb-212 Isotope Generator: Proprietary isotope-generation system that secures Pb-212 for clinical trials and commercial operations, supporting Perspective Therapeutics' radiopharmaceutical programs
  • Theranostics: Peptide-targeted, combined diagnostic-therapeutic platform that uses Pb-203 to diagnose tumors and Pb-212 alpha-particles to treat them, integrating precise targeting with radiopharmaceutical therapy
  • Targeted Alpha-Particle Radiotherapy: Alpha-particle-based, focused radiotherapy that delivers lethal radiation to cancer cells, inducing DNA damage and cell death while limiting exposure to healthy tissue

Key contacts

🔒
🔒

Financial details

🔒

1.2 - Competitors and similar companies to Perspective Therapeutics

Ajax Therapeutics Logo

Ajax Therapeutics

HQ: United States Website
  • Description: Provider of therapies targeting cytokine signaling in hematologic malignancies, including AJ1-10502, a next-generation Type II JAK2 inhibitor for myeloproliferative neoplasms with improved efficacy and selectivity over Type I JAK2 inhibitors, and developer of a pipeline of selectively targeted small molecules via a partnership with Schrödinger using advanced computational chemistry and structure-based technologies.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Ajax Therapeutics company profile →
Theragnostics Logo

Theragnostics

HQ: United Kingdom Website
  • Description: Provider of diagnostic and therapeutic agents, aiming to deliver a complete portfolio of products to transform patient care from initial diagnosis to therapy; established as Theragnostics Ltd in 2015, with a US presence via Theragnostics Inc (2016) and an office in Boston, MA.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Theragnostics company profile →
Ultivue Logo

Ultivue

HQ: United States Website
  • Description: Provider of tissue imaging and multiplex biomarker assay solutions for precision medicine research, including InSituPlex DNA-barcoded antibody technology, custom assay development, pre-optimized ready-to-use multiplex staining kits, specialized AI tools and full lifecycle image analysis for multiplex immunofluorescence, and OmniVUE customizable biomarker panel design kits.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Ultivue company profile →
iOnctura Logo

iOnctura

HQ: Switzerland Website
  • Description: Provider of clinical-stage biopharmaceutical therapies targeting immunosuppression in the tumor microenvironment to improve immune checkpoint therapies. Pipeline includes Roginolisib (IOA-244), a PI3Kδ inhibitor in Phase Ib/II for solid tumors and hematological malignancies; IOA-289, an autotaxin inhibitor in Phase Ib/II for pancreatic and other CAF-driven tumors; and preclinical IOA-359 (TGF-β) and IOA-237 (CD73 mAb).
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full iOnctura company profile →
Checkpoint Therapeutics Logo

Checkpoint Therapeutics

HQ: United States Website
  • Description: Provider of immuno-oncology and targeted oncology therapies in development, advancing a pipeline including cosibelimab (fully human anti-PD-L1 monoclonal antibody), olafertinib (oral third-generation irreversible EGFR inhibitor for NSCLC), CK-103 (BET bromodomain inhibitor), CK-302 (agonistic GITR antibody), and an anti-CAIX antibody for renal cell carcinoma, plus product purchases, in-licensing and co-development.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Checkpoint Therapeutics company profile →
🔒

2.M&A buyers

2.1 Potential strategic acquirers in the sector

🔒
🔒
🔒
🔒 View all strategic buyers with complete profiles
Start Free Trial →

2.2 - Strategic buyer groups for Perspective Therapeutics

🔒

Buyer group 1: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔒

Buyer group 2: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔒

Buyer group 3: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →

3. Investors and private equity firms

3.1 - Buyout funds investing in similar companies to Perspective Therapeutics

2.2 - Growth funds investing in similar companies to Perspective Therapeutics

🔒 View all growth equity funds with complete profiles
Start Free Trial →

4 - Top valuation comps for Perspective Therapeutics

4.2 - Public trading comparable groups for Perspective Therapeutics

🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →

4.3 - M&A Transactions similar to Perspective Therapeutics

Selected M&A transactions

Date Target Description Buyer(s) Relevance EV EV/Revenue EV/EBITDA
🔒 View all M&A transactions with complete deal terms
Request Free Trial Now →

Frequently Asked Questions

About Perspective Therapeutics

What does Perspective Therapeutics do?

Perspective Therapeutics is a provider of radiopharmaceutical cancer theranostics and targeted alpha-particle radiotherapy, including Pb-203 diagnostics and Pb-212 treatment via targeting peptides. Offers clinical programs VMT-α-NET for neuroendocrine tumors and VMT01 for metastatic melanoma, and a proprietary Pb-212 isotope generator to secure key isotopes for clinical trials and commercial operations.

Who are Perspective Therapeutics's competitors?

Perspective Therapeutics's competitors and similar companies include Ajax Therapeutics, Theragnostics, Ultivue, iOnctura, and Checkpoint Therapeutics.

Where is Perspective Therapeutics headquartered?

Perspective Therapeutics is headquartered in United States.

How many employees does Perspective Therapeutics have?

Perspective Therapeutics has 1,000 employees 🔒.

When was Perspective Therapeutics founded?

Perspective Therapeutics was founded in 2010 🔒.

What sector and industry vertical is Perspective Therapeutics in?

Perspective Therapeutics is in the Enterprise Software 🔒 sector and industry

M&A Buyers & Acquirers for Perspective Therapeutics

Who are the top strategic acquirers in Perspective Therapeutics's sector and industry

Top strategic M&A buyers and acquirers in Perspective Therapeutics's sector include ████████, ██████████, ██████, ████████, and ██████████ 🔒.

Which M&A buyer groups are most relevant for Perspective Therapeutics?

Top strategic M&A buyers groups and sectors for Perspective Therapeutics include █████████████████ , ████████████████, █████████████, ████████████, and ████████████████ 🔒.

Financial Investors investing in Perspective Therapeutics's sector and industry vertical

Which are the top PE firms investing in Perspective Therapeutics's sector and industry vertical?

Top PE firms investing in Perspective Therapeutics's sector and industry vertical include ████████, ██████████, ████████, and ██████████ 🔒.

Who are the top buyout funds acquiring in Perspective Therapeutics's sector and industry vertical?

Active PE funds and buyout funds acquiring companies in Perspective Therapeutics's sector and industry vertical include █████████, ██████████, ████████████, and ████████████ 🔒.

Who are the top growth equity funds investing in companies in Perspective Therapeutics's sector and industry vertical?

Growth funds and venture capital funds investing in companies similar to Perspective Therapeutics include █████████, ██████████, ████████████, and ████████████ 🔒.

Valuation benchmarks of companies in Perspective Therapeutics's sector and industry

Which are the key public companies that are relevant trading comps benchmarks for Perspective Therapeutics?

The key public trading comparables and valuation benchmarks for Perspective Therapeutics include █████████, ██████████, ████████████, and ████████████ 🔒.

Which are the key trading comparable groups for Perspective Therapeutics for public valuation benchmarks?

Our platform tracks detailed public trading comparable groups and valuation benchmarks for Perspective Therapeutics with complete valuation multiples, growth metrics, and profitability data. Access the full database to benchmark your company against relevant public comparables.

What are recent M&A transactions in Perspective Therapeutics's sector and industry vertical?

Our platform tracks relevant M&A transactions comparables and valuation benchmarks for Perspective Therapeutics with complete deal terms, valuation multiples, and strategic rationale. Access the full database to benchmark pricing and identify active acquirers.

What are recent capital raises and funding rounds in Perspective Therapeutics's' sector and industry vertical?

Access recent funding rounds and capital raises in Perspective Therapeutics's sector and industry vertical including growth equity, venture capital, and buyout investments. Our database includes round size, lead investors and valuations.

Ready to Find the Right Buyers?

Access complete buyer lists, valuation data, and M&A intelligence for Perspective Therapeutics